(Washington, DC) – The Food and Drug Administration has approved a blood test to detect conditions in the brain tied to Alzheimer’s disease. The test, called Lumipulse, measures two proteins found in the blood’s plasma to find if a patient has plaques in the brain. Tests up until now have been more invasive using brain scans and a spinal tap to confirm the presence of plaques.
An FDA spokesperson said, the clearance is an important step for Alzheimer’s disease diagnosis, making it easier and more accessible for patients in earlier stages.
Comments